Scarica l'app Stockscreener
13.57
0.37%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$13.62
Aprire:
$13.69
Volume 24 ore:
6.46M
Relative Volume:
2.57
Capitalizzazione di mercato:
$2.04B
Reddito:
-
Utile/perdita netta:
$-647.68M
Rapporto P/E:
-2.3933
EPS:
-5.67
Flusso di cassa netto:
$-594.49M
1 W Prestazione:
+19.35%
1M Prestazione:
+59.84%
6M Prestazione:
+21.92%
1 anno Prestazione:
-5.70%
Intervallo 1D:
$13.12
$14.23
Intervallo di 1 settimana:
$11.12
$14.23
Portata 52W:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.57 | 2.04B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-06 | Iniziato | Goldman | Buy |
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations (BHVN) - Seeking Alpha
Biohaven Ltd (BHVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biohaven Ltd (BHVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates - Insider Monkey
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(BHVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Biohaven (BHVN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
How Biohaven’s Precision Immunology Pipeline Updates Will Impact Biohaven (BHVN) Investors - simplywall.st
Biohaven | DEF 14A: Definitive information statements - Moomoo
Biohaven Ltd (BSP:BHVN34) Stock PDF (Updated: 2026/06/15) - GuruFocus
A Look At Biohaven (BHVN) Valuation After Fresh Pipeline Updates For BHV 8100 BHV 1300 And BHV 1400 - simplywall.st
Is Biohaven (BHVN) Quietly Reframing Its Investment Story Around Brain Energy and Precision Immunology? - Yahoo Finance
Biohaven (BHVN) Valuation Check After New R&D Milestones In Immunology Neuroscience And Metabolic Programs - Yahoo Finance
Biohaven Pharmaceutical Holding Company Ltd (BHVN) News, Articles, Events & Latest Updates - Stocktwits
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%? - Yahoo Finance
Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)? - Sahm
How (BHVN) Movements Inform Risk Allocation Models - Stock Traders Daily
Biohaven (BHVN) Tops Valuation Grades Among Small-Cap Healthcare Stocks - GuruFocus
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Biohaven Starts First Human Trial of BHV-8100 for Neurological, Retinal and Inflammatory Diseases - marketscreener.com
Biohaven begins first human trial of brain-penetrant drug BHV-8100 - StreetInsider
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PR Newswire
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY) - The Globe and Mail
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Goldman Sachs Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
William Blair Maintains Biohaven(BHVN.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Biohaven’s Opakalim Shows Strong Seizure Control and Superior Tolerability in Epilepsy Clinical Trials - Minichart
Biohaven Ltd. (BHVN) Shares Slide 6.7%—Pressing Key Support at $10.00getLinesFromResByArray error: size == 0 - lwvtexas.org
Biohaven Showcases Promising Opakalim Epilepsy Data at R&D Day - TipRanks
Biohaven reports strong opakalim seizure control and MoDE/TRAP biomarker wins ahead of pivotal trials - TradingView
Biohaven (BHVN) unveils epilepsy, Graves’ and IgA nephropathy data at 2026 R&D Day - Stock Titan
BiohavenDespite Today's Gains, I Remain Skeptical (NYSE:BHVN) - Seeking Alpha
Biohaven (BHVN) reports positive Phase 1b autoimmune data - grafa.com
Biohaven stock jumps on positive drug trial results By Investing.com - Investing.com South Africa
Biohaven stock jumps on positive drug trial results - Investing.com
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Biohaven stock after positive drug trial data - Investing.com Australia
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):